Induction of γ-glutamyl transpeptidase mRNA by platinum complexes in a human ovarian carcinoma cell line

Oncology Research

Volumn 8, Issue 10-11, 1996, Pages 415-423

  El Akawi, Zeyad ^a   Zdanowicz, Joseph ^a   Creaven, Patrick J ^a   Abu Hadid, Mahmoud ^a   Perez, Raymond ^a   Pendyala, Lakshmi ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

cisplatin; glutathione; oxaliplatin; glutamyl cysteine synthetase; glutamyl transpeptidase

Indexed keywords

CISPLATIN; GAMMA GLUTAMYLTRANSFERASE; MESSENGER RNA; OXALIPLATIN; PLATINUM COMPLEX;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0030431118     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. 1. Meister, A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol. Ther. 51:155-194; 1991.
2. 2. Deleve, L. D.; Kaplowitz, N. Glutathione metabolism and its role in hepatotoxicity. Pharmacol. Ther. 52: 287-305; 1991.
3. 3. Tew, K. D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 54:4313-4320; 1994.
4. 4. Perez, R. P.; Hamilton, T. C.; Ozols, R. F. Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems. Pharmacol. Ther. 48:19-27; 1990.
5. 5. Behrens, B. C.; Hamilton, T. C.; Masuda, H.; Grotzinger, K. R.; Whang-Peng, J.; Louie, K. G.; Knutsen, T.; McKoy, W. M.; Young, R. C.; Ozols, R. F. Characterization of a cis-diamminedichloroplatinum (II) resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47: 414-418; 1987.
6. 6. Richon, V. M.; Schulte, N,; Eastman, A. Multiple mechanisms of cellular resistance to platinum coordination complexes. Cancer Res. 47:2056-2061; 1987.
7. 7. Bailey, H. H.; Gipp, J. J.; Ripple, M.; Wilding, G.; Mulcahy, R. T. Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels. Cancer Res. 52:5115-5118; 1992.
8. 8. Moscow, J. A.; Dixon, K. H. Glutathione-related enzymes, glutathione and multidrug resistance. Cytotechnology 12:155-170; 1993.
9. 9. Mulders, T. M. T; Keizer, H. J.; Breimer, D. D.; Mulder, G. J. In vivo characterization and modulation of the glutathione/glutathione S-transferase system in cancer patients. Drug Metab. Rev. 27:191-229; 1995.
10. 10. Rairkar, A.; Ali-Osman, F. Modulation of DNA ligase activities in a BCNU and cisplatin resistant human malignant astrocytoma cell line by glutathione depletion. Proc. Amer. Assoc. Cancer Res. Annu. Meet. 33:7; 1992.
11. 11. Ali-Osman, F.; Rairkar, A. Alterations in DNA polymerases α, β and δ in human brain tumor cells after glutathione depletion. Proc. Amer. Assoc. Cancer Res. Annu. Meet. 33:497; 1992.
12. 12. Chen, G.; Zeller, W. J. Augmentation of cisplatin cytotoxicity in vivo by DL-buthionine sulfoximine in DDP sensitive and resistant rat ovarian tumors and its relation to DNA interstrand cross links. Anticancer Res. 11: 2231-2238; 1991.
13. 13. Lai, G.; Ozols, R.; Young, R.; Hamilton, T. Effect of glutathione on DNA repair in cisplatin resistant human ovarian cancer cell lines. J. Natl. Cancer Inst. 81: 535-539; 1989.
14. 14. Ishikawa, T.; Ali-Osman, F. Glutathione-associated cis-diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. J. Biol. Chem. 268:20116-20125; 1993.
15. 15. Ishikawa, T.; Wright, C. D.; Ishizuka, H. GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum(II)-resistant human leukemia HL-60 cells and downregulated by cell differentiation. J. Biol. Chem. 269:29085-29093; 1994.
16. 16. Zaman, G. J. R.; Lankelma, J.; Tellingen, O. V.; Beijnen, J.; Dekker, H.; Paulusma, C.; Oude Elferink, R. P. J.; Bass, F.; Borst, P. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc. Natl. Acad. Sci. USA 92: 7690-7694; 1995.
17. 17. Versantvoort, C. H.; Broxterman, H. J.; Bagrij, T.; Scheper, R. J.; Twentyman, P. R. Regulation by glutathione of drug transport in multidrug-resistant human lung tumor cell lines overexpressing multidrug resistance-assocíated protein. Br. J. Cancer 72:82-89; 1995.
18. 18. Meister, A. Novel drugs that affect glutathione metabolism. In: Woolley, P. V., III; Tew, K. D. eds. Mechanisms of drug resistance in neoplastic cells. New York: Academic Press; 1988:pp. 99-126.
19. 19. Godwin, A. K.; Meister, A.; O'Dwyer, P. J.; Huang, C. S.; Hamilton, T. C.; Anderson, M. E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA 89:3070-3074; 1992.
20. 20. Mulcahy, R. T; Bailey, H. H.; Gipp, J. J. Up-regulation of γ-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels. Cancer Chemother. Pharmacol. 34:67-71; 1994.
21. 21. Mulcahy, R. T.; Untawale, S.; Gipp, J. Transcriptional upregulation of γ-glutamyl cysteine synthetase gene expression in melphalan-resistant human prostate carcinoma cells. Mol. Pharmacol. 46:909-914; 1994.
22. 22. Yao, K.; Godwin, A. K.; Johnson, S. W.; Ozols, R. F.; O'Dwyer, P. J.; Hamilton, T. C. Evidence for altered regulation of γ-glutamylcysteine synthetase gene expression among cisplatin sensitive and cisplatin resistant human ovarian carcinoma cell lines. Cancer Res. 55:4367-4374; 1995.
23. 23. Ishikawa, T.; Wright, C. D. GS-X pump and γ-glutamylcysteine synthetase are co-overexpressed in cisplatinresistant human leukemia HL-60 cells. Proc. Amer. Assoc. Cancer Res. Annu. Meet. 36:313; 1995.
24. 24. El-akawi, Z.; Abu-hadid, M.; Perez, R.; Glavy, J.; Zdanowicz, J.; Creaven, P. J.; Pendyala, L. Altered regulation of glutathione metabolism in oxaliplatin resistant A2780 ovarian carcinoma cells. Cancer Lett. 105:5-14; 1996.
25. 25. El-akawi, Z.; Abu-hadid, M.; Perez, R.; Glavy, J.; Creaven, P. J.; Pendyala, L. Regulation of glutathione in oxaliplatin resistant ovarian carcinoma cell lines. In: Pinedo, H. M.; Schomagel, J. H., eds. Platinum and other model coordination compounds in cancer chemotherapy 2. Proceedings of the Seventh International Symposium on Platinum Compounds in Cancer Chemotherapy. New York: Plenum Press; 1995:p. 175.
26. 26. Misset, J. L.; Kidani, Y.; Gastiaburu, J.; Jasmin, C.; Levi, F.; Boughattas, N.; Lemaigre, G.; Caussanel, J. P.; Brienza, S.; Kim Triana, B.; Goldschmidt, M.; Musset, M.; Mauvernay, R. Y.; Mathe, G. Oxalatoplatinum (1-OHP): experimental and clinical studies. In: Howell, S. B., ed. Platinum and other metal coordination compounds in cancer chemotherapy. New York: Plenum Press; 1991: pp. 369-375.
27. 27. Mathe, G.; Kidani, Y.; Segiguchi, M.; Eriguchi, M.; Fredj, G.; Peytavin, G.; Misset, J. L.; Brienza, S.; de Vassals, F.; Chenu, E.; Bourut, C. Oxalato-platinum or oxaliplatin, a third generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed. Pharmacother. 43:237-250; 1991.
28. 28. Christian, M. The current status of new platinum analogs. Semin. Oncol. 19:720-733; 1992.
29. 29. Extra, J. M.; Espie, M.; Calvo, R; Ferme, C.; Mignot, L.; Marty, M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol. 25: 299-303; 1990.
30. 30. Warren, W.; Wheat, T.; Knudsen, P. Rapid analysis and quantitation of PCR products by high performance liquid chromatography. BioTechniques 11:250-255; 1991.
31. 31. Chomczynski, P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. BioTechniques 15:532-537; 1993.
32. 32. Gipp, J. J.; Chang, C.; Mulcahy, T. Cloning and nucleotide sequence of a full-length cDNA for human liver γ-glutamylcysteine synthetase. Biochem. Biophys. Res. Commun. 185:29-35; 1992.
33. 33. Rajpert-De Meyts, E.; Heisterkamp, N.; Groffen, J. Cloning and nucleotide sequence of human γ-glutamyl transpeptidase. Proc. Natl. Acad. Sci. USA 85: 8840-8844; 1988.
34. 34. Ponte, P.; Ng, S. Y.; Engel, J.; Gunning, P.; Kedes, L. Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucl. Acids Res. 12:1687-1696; 1984.
35. 35. Yao, K.; Godwin, A.; Ozols, R. F.; Hamilton, T. C.; O'Dwyer, P. J. Variable baseline γ-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. Cancer Res. 53: 3662-3666; 1993.
36. 36. Naftalin, L.; Sexton, M.; Whitaker, J. F.; Tracey, D. A routine procedure for estimating serum γ-glutamyi transpeptidase activity and its clinical applications. Clin. Chim. Acta 26:293-296; 1969.
37. 37. Fahey, R. C.; Newton, G. L. Determination of low molecular weight thiols using monobromobimane fluorescent labelling and high performance liquid chromatography. Meth. Enzymol. 113:85-96; 1985.
38. 38. Anderson, M. E. Determination of glutathione and glutathione disulfide in biological samples. Meth. Enzymol. 143:548-555; 1987.
39. 39. Lowry, O. H.; Rosenbrough, M. T; Fair, A. L.; Randall, R. J. Protein measurement with folin phenol reagent. J. Biol. Chem. 193:265; 1951.
40. 40. Pendyala, L.; Creaven, P. J. Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trial. Cancer Epidemiol. Biomarkers Prevent. 4:245-251; 1995.
41. 41. Kizu, R.; Higashi, S.; Kidani, Y.; Miyazaki, M. Pharmacokinetics of (1R,2R-diaminocyclohexane) oxalatoplatinum (II) in comparison with cisplatin following a single intravenous injection in rabbits. Cancer Chemother. Pharmacol. 31:475-480; 1993.
42. 42. Creaven, P. J.; Pendyala, L.; Perez, R.; Meropol, N. J.; Lowen, G. M.; Levine, E.; Wilkes, J.; Wilkes, K.; Raghavan, D. Cisplatin modulation by N-phosphanoacetyl-L-aspartate in patients with advanced solid tumors. In: Pinedo, H. M.; Schornaget, J. H., eds. Platinum and other model coordination compounds in cancer chemotherapy 2. Proceedings of the Seventh International Symposium on Platinum Compounds in Cancer Chemotherapy. New York: Plenum Press; 1995:p.59.
43. 43. Pendyala, L.; Creaven, P. J. In vitro cytotoxicity, protein binding, red blood cell partitioning and biotransformation of oxaliplatin. Cancer Res. 53:5970-5976; 1993.
44. 44. Hanigan, M. H. Expression of γ-glutamyl transpeptidase provides tumor cells with a selective growth advantage at physiological concetrations of cyst(e)ine. Carcinogenesis 16:181-185; 1995.
45. 45. Eastman, A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2:275-280; 1990.
46. 46. Tsuchida, S.; Hoshino, K.; Sato, T.; Ito, N.; Sato, K. Purification of γ-glutamyltransferase from rat hepatomas and hyperplastic nodules and comparison with the enzyme from rat kidney. Cancer Res. 39:4200-4205; 1979.
47. 47. Ding, J. L.; Smith, G. D.; Peters, T. J. The turnover of hepatoma cell γ-glutamyl transferase. FEBS Lett. 142:207-209; 1982.
48. 48. Anderson, M. E.; Meister, A. Transport and direct utilization of γ-glutamylcyst(e)ine for glutathione synthesis. Proc. Natl. Acad. Sci. USA. 80:707-711; 1983.
49. 49. Hanigan, M. H.; Pitot, H. C. Gamma-glutamyl transpeptidase - its role in hepatocarcinogenesis. Carcinogenesis 6:165-172; 1985.
50. 50. Lewis, A. D.; Hayes, J. D.; Wolf, C. R. Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. Carcinogenesis 9:1283-1287; 1988.
51. 51. Bier, H.; Bergler, W.; Mende, S.; Granzer, U. Glutathione content and γ-glutamyltranspeptidase activity in squamous cell head and neck cancer xenografts. Arch. Otorhinolaryngol. 245:166-169; 1988.
52. 52. Pratesi, G.; Dal Bo, L.; Paolicchi, A.; Tonarelli, P.; Tongiani, R.; Zunino, F. The role of glutathione dependent system in tumor sensitivity to cisplatin: a study of human tumor xenografts. Ann. Oncol. 6:283-289; 1995.
53. 53. Hanigan, M. H.; Bendall, H. Induction of γ-glutamyl transpeptidase in the human ovarian tumor cell line A2780, sensitivity to cisplatin. Proc. Am. Assoc. Cancer Res. Annu. Meet. 36:345; 1995.
54. 54. Hochwald, S. N.; Harrison, L. E.; Rose, M.; Anderson, M.; Burt, M. E. γ-glutamyl transpeptidase mediation of tumor glutathione utilization in vivo. J. Natl. Cancer Inst. 88:193-197; 1996.